Umlobi: Clyde Lopez
Usuku Lokudalwa: 24 Ujulayi 2021
Ukuvuselela Usuku: 1 Ujulayi 2025
Anonim
Niacin (feat. Billy Sheehan) - I Miss You (Like I Miss The Sun) (Live In Tokyo 2005)
Ividiyo: Niacin (feat. Billy Sheehan) - I Miss You (Like I Miss The Sun) (Live In Tokyo 2005)

-Delile

I-Niacin uhlobo lwevithamini B3. Kutholakala ekudleni okufana nemvubelo, inyama, inhlanzi, ubisi, amaqanda, imifino eluhlaza, nezinhlamvu zokusanhlamvu. INiacin nayo ikhiqizwa emzimbeni kusuka ku-tryptophan, etholakala ekudleni okuqukethe amaprotheni. Uma ithathwa njengesengezo, i-niacin ivame ukutholakala ihlangene namanye amavithamini B.

Ungadidanisi i-niacin ne-NADH, niacinamide, inositol nicotinate, IP-6, noma i-tryptophan. Bona izinhlu ezihlukile zalezi zihloko.

Amafomu kadokotela we-niacin avunywa yi-US Food and Drug Administration (FDA) ye-cholesterol ephezulu nokwandisa amazinga ohlobo oluthile lwe-cholesterol enhle, eyaziwa njenge-HDL. Izithako ze-Niacin nemikhiqizo kadokotela nayo ithathwa ngomlomo ukuvikela ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagra.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze I-NIACIN zimi kanje:


Cishe iyasebenza ...

  • Amazinga angajwayelekile we-cholesterol noma amafutha egazi (i-dyslipidemia). Eminye imikhiqizo ye-niacin ivunywa yi-U.S. Food and Drug Administration (FDA) njengemikhiqizo kadokotela yokwelapha amazinga angajwayelekile wamafutha egazi. Le mikhiqizo ye-niacin kadokotela imane iza ngamandla aphezulu ka-500 mg noma ngaphezulu. Izinhlobo zokwengezelwa ekudleni kwe-niacin zivame ukuza ngamandla ka-250 mg noma ngaphansi. Njengoba imithamo ephezulu kakhulu ye-niacin iyadingeka ekuthuthukiseni amazinga e-cholesterol, i-niacin yokudla edliwayo ngokuvamile ayifanele. I-Niacin ingahlanganiswa nezinye izidakamizwa ezehlisa i-cholesterol lapho ukudla kanye nokwelashwa kwesidakamizwa esisodwa kunganele. I-Niacin ithuthukisa amazinga e-cholesterol, kepha ayithuthukisi imiphumela yenhliziyo efana nokuhlaselwa yinhliziyo nokushaywa unhlangothi.
  • Isifo esidalwa ukushoda kwe-niacin (pellagra). I-Niacin ivunyelwe yi-U.S. Food and Drug Administration (FDA) yalokhu kusetshenziswa. Kodwa-ke, i-niacin ingadala "ukuqhuma" (ububomvu, ukulunywa, nokuhayiza). Ngakho-ke omunye umkhiqizo, obizwa nge-niacinamide, kwesinye isikhathi uyathandwa ngoba awubangeli lo mphumela oseceleni.

Kungenzeka kusebenze ...

  • Amazinga angajwayelekile amafutha egazi kubantu abane-HIV / AIDS. Ukuthatha i-niacin kubonakala kuthuthukisa amazinga e-cholesterol namafutha egazi abizwa nge-triglycerides ezigulini ezikulesi simo.
  • Ukuqoqwa kwezimpawu ezandisa ubungozi besifo sikashukela, isifo senhliziyo, nesifo sohlangothi (isifo se-metabolic syndrome). Ukuthatha i-niacin kubonakala kukhuphula amazinga e-high-density lipoprotein (HDL noma "okuhle") cholesterol futhi kunciphise amazinga amafutha egazi abizwa nge-triglycerides kubantu abane-metabolic syndrome. Ukuthatha i-niacin kanye ne-omega-3 fatty acid kadokotela kubonakala kusebenza kangcono kakhulu.

Akusebenzi ...

  • Isifo senhliziyo. Ucwaningo lwekhwalithi ephezulu lukhombisa ukuthi i-niacin ayivimbeli isifo senhliziyo noma isifo sohlangothi kubantu abathatha i-niacin ukuvimbela noma ukwelapha isifo senhliziyo. INiacin nayo ayikhonjiswanga ukunciphisa ubungozi bokufa. I-Niacin akufanele ithathwe ukwelapha noma ukuvimbela isifo senhliziyo.

Ubufakazi obanele bokukala ukusebenza kwe ...

  • Ukuqina kwemithambo yegazi (i-atherosclerosis). Ukuthatha i-niacin ngomlomo kanye nemithi ebizwa nge-bile acid sequestrants kunganciphisa ukuqina kwemithambo emadodeni analesi simo. Kubonakala kusebenza kahle emadodeni anamafutha aphezulu egazi abizwa nge-triglycerides. Kepha ukuthatha i-niacin kubonakala kunganciphisi ukuqina kwemithambo yegazi ezigulini ezinesimo esibizwa nge-peripheral arterial disease (PAD). Futhi, i-niacin ayivimbeli izehlakalo zenhliziyo ezifana nokuhlaselwa yinhliziyo noma isifo sohlangothi.
  • Isifo i-Alzheimer. Abantu abadla inani eliphakeme le-niacin ekudleni nakuma-multivitamin babonakala benengozi engezansi yokuthola isifo se-Alzheimer kunabantu abadla i-niacin encane. Kepha abukho ubufakazi bokuthi ukuthatha isithasiselo se-niacin kuyasiza ukuvimbela isifo se-Alzheimer.
  • Isifo senkwethu. Abantu abadla ukudla okuphezulu nge-niacin bangase babe nethuba elincishisiwe lokuthuthukisa ukonakala kwenyukliya. I-Nuclear cataract uhlobo oluvame kakhulu lwe-cataract. Umphumela wokuthatha isengezo se-niacin awaziwa.
  • Ukutheleleka kwamathumbu okubangela isifo sohudo (ikholera). Ukuthatha i-niacin ngomlomo kubonakala kunciphisa isifo sohudo kubantu abanekholera.
  • Ukungasebenzi kwe-Erectile (ED). Ukuthatha i-niacin ekhishwe isikhathi eside ngesikhathi sokulala amasonto e-12 kubonakala kusiza amadoda ane-ED namazinga aphezulu e-lipid agcine ukwakhiwa ngesikhathi sokuya ocansini.
  • Izinga eliphakeme le-phosphate egazini (hyperphosphatemia). Abantu abanokwehluleka kwezinso bangaba namazinga aphezulu egazi e-phosphate. Olunye ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-niacin kunganciphisa amazinga egazi e-phosphate kubantu abanezifo zezinso zokugcina kanye namazinga aphezulu we-phosphate yegazi. Kepha olunye ucwaningo lukhombisa ukuthi ukuthatha i-niacin akwehlisi amazinga e-phosphate egazi kubantu abasebenzisa nemithi esetshenziselwa ukwehlisa amazinga e-phosphate egazi.
  • Ukuvaleka komthambo esweni (ukuvalwa kwe-vein retinal): Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-niacin kungahle kuthuthukise ukubona kwabantu kubantu abanalesi simo.
  • Isifo se-Sickle cell: Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-niacin akuwenzi ngcono amazinga amafutha egazi kubantu abane-sickle cell disease.
  • Izinduna.
  • Ukuphazamiseka kokusebenzisa utshwala.
  • Ukusebenza kwezemidlalo.
  • Ukunakwa kokushoda-i-hyperactivity disorder (ADHD).
  • Ukucindezeleka.
  • Isiyezi.
  • Imibono emibono yezidakamizwa.
  • Migraine.
  • Ukugula kokunyakaza.
  • Ischizophrenia.
  • Ezinye izimo.
Kudingeka ubufakazi obuningi ukukala i-niacin yalokhu kusetshenziswa.

INiacin imuncwa ngumzimba lapho ichithwa emanzini futhi ithathwa ngomlomo. Ishintshelwa ku-niacinamide uma ithathwa ngamanani amakhulu kunalokho okudingeka emzimbeni.

I-Niacin iyadingeka ekusebenzeni okufanele kwamafutha noshukela emzimbeni nokugcina amaseli aphilile. Emithamo ephezulu, i-niacin ingasiza abantu abanesifo senhliziyo ngenxa yemiphumela yayo ezuzisayo ekunqandeni. Kungaphinde kuthuthukise amazinga ohlobo oluthile lwamafutha abizwa nge-triglycerides egazini.

Ukushoda kwe-Niacin kungadala isimo esibizwa nge-pellagra, esidala ukucasuka kwesikhumba, isifo sohudo kanye nokuwohloka komqondo. I-Pellagra yayivamile ekuqaleni kwekhulu lama-20, kepha ayisajwayelekile kakhulu manje, ngoba okunye ukudla okuqukethe ufulawa manje sekuqiniswe nge-niacin. IPellagra isuswe cishe emasikweni asentshonalanga.

Abantu abanokudla okungafanele, ukuphuza ngokweqile, kanye nezinye izinhlobo zezimila ezikhula kancane ezibizwa ngokuthi izicubu ze-carcinoid zingaba sengozini yokushoda kwe-niacin. Lapho ithathwa ngomlomo: UNiacin unjalo CISHE UVIKILE kubantu abaningi lapho bethathwe ngokufanele. Imikhiqizo kadokotela equkethe i-niacin iphephile uma ithathwa njengokuyalelwa. Ukudla okuqukethe i-Niacin noma izithasiselo ze-niacin ziphephile lapho zithathwa ngemithamo engaphansi kuka-35 mcg nsuku zonke.

Umphumela ovamile we-niacin ukusabela okweqile. Lokhu kungadala ukushisa, ukuqaqamba, ukulunywa, nokubomvu kobuso, izingalo, nesifuba, kanye nekhanda. Ukuqala ngemithamo emincane ye-niacin nokuthatha ama-aspirin angama-325 mg ngaphambi komthamo ngamunye we-niacin kuzosiza ukunciphisa ukusabela kokugobhoza. Imvamisa, lokhu kusabela kuyaphela njengoba umzimba ujwayela umuthi. Utshwala bungenza ukusabela okugijimayo kube kubi kakhulu. Gwema inani elikhulu lotshwala ngenkathi uthatha i-niacin.

Eminye imiphumela emibi emibi ye-niacin ukucasuka kwesisu, igesi emathunjini, isiyezi, ubuhlungu emlonyeni nezinye izinkinga.

Lapho kuthathwa imithamo engaphezu kuka-3 amagremu ngosuku lwe-niacin, imiphumela emibi kakhulu ingenzeka. Lokhu kufaka phakathi izinkinga zesibindi, i-gout, izilonda zomgudu wokugaya ukudla, ukungaboni kahle, ushukela ophakeme wegazi, ukushaya kwenhliziyo okungajwayelekile, nezinye izinkinga ezinkulu.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: UNiacin unjalo CISHE UVIKILE kwabesifazane abakhulelwe nabancelisayo lapho bethathwa ngomlomo ngamanani anconyiwe. Inani eliphakanyisiwe le-niacin labesifazane abakhulelwe noma abancelisa ibele lingu-30 mg ngosuku kwabesifazane abangaphansi kweminyaka engu-18 ubudala, kanye no-35 mg wabesifazane abaneminyaka engaphezu kwengu-18.

Izingane: UNiacin unjalo CISHE UVIKILE lapho ithathwa ngomlomo ngamanani anconyiwe eqembu ngalinye leminyaka. Kepha izingane kufanele zigweme ukuthatha imithamo ye-niacin ngaphezu kwemikhawulo ephezulu yansuku zonke, eyi-10 mg yezingane ezineminyaka engu-1-3 ubudala, i-15 mg yezingane ezineminyaka engu-4-8 ubudala, i-20 mg yezingane ezineminyaka engu-9-13, kanye 30 mg wezingane ezineminyaka engu-14-18 ubudala.

Ukungezwani komzimba: I-Niacin ingase yenze ukungezwani komzimba kubhebhethekise i-histamine, ikhemikhali elibhekele izimpawu zomzimba, ukuthi ikhishwe.

Isifo senhliziyo / i-angina engazinzile: Inani elikhulu le-niacin lingakhuphula ubungozi bokushaya kwenhliziyo okungajwayelekile. Sebenzisa ngokuqapha.

Isifo seCrohnAbantu abanesifo sikaCrohn bangaba namazinga aphansi e-niacin futhi badinge ukwengezwa ngesikhathi sokuqhuma.

Isifo sikashukela: I-Niacin ingakhuphula ushukela wegazi. Abantu abanesifo sikashukela abathatha i-niacin kufanele bahlole ushukela egazini labo ngokucophelela.

Isifo se-gallbladder: I-Niacin ingenza isifo se-gallbladder sibe sibi kakhulu.

Gout: Inani elikhulu le-niacin lingaletha ku-gout.

Isifo sezinso: I-Niacin ingaqongelela kubantu abanesifo sezinso. Lokhu kungadala ingozi.

Isifo sesibindi: I-Niacin ingakhuphula ukulimala kwesibindi. Ungasebenzisi amanani amakhulu uma unesifo sesibindi.

Izilonda zesisu noma zamathumbu: I-Niacin ingenza izilonda zibe zimbi kakhulu. Ungasebenzisi amanani amakhulu uma unezilonda.

Umfutho wegazi ophansi kakhulu: I-Niacin inganciphisa umfutho wegazi futhi yenze isimo sibe sibi kakhulu.

Ukuhlinzwa: I-Niacin ingaphazamisa ukulawulwa kukashukela egazini ngesikhathi nangemva kokuhlinzwa. Yeka ukuthatha i-niacin okungenani amasonto ama-2 ngaphambi kokuhlinzwa okuhleliwe.

Amafutha afaka azungeze imisipha (tendon xanthomas): I-Niacin ingakhuphula ubungozi bokutheleleka kuma-xanthomas.

Izinkinga ze-thyroid: I-Thyroxine iyi-hormone ekhiqizwa yindlala yegilo. I-Niacin ingehlisa amazinga egazi e-thyroxine. Lokhu kungabhebhethekisa izimpawu zezifo ezithile ze-thyroid.

Maphakathi
Qaphela ngale nhlanganisela.
Utshwala (i-Ethanol)
I-Niacin ingadala ukugeleza nokuchachamba. Ukuphuza utshwala kanye ne-niacin kungenza ukuqhuma nokushaywa kube kubi kakhulu. Kukhona nokunye ukukhathazeka ngokuthi ukuphuza utshwala nge-niacin kungakhuphula amathuba okuba nomonakalo wesibindi.
I-Allopurinol (iZyloprim)
I-Allopurinol (iZyloprim) isetshenziselwa ukwelapha i-gout. Ukuthatha imithamo emikhulu ye-niacin kungalimaza i-gout futhi kwehlise ukusebenza kwe-allopurinol (iZyloprim).
I-Clonidine (Catapres)
I-Clonidine ne-niacin yomibili ingcindezi yegazi ephansi. Ukuthatha i-niacin ne-clonidine kungadala ukuthi umfutho wegazi lakho ube phansi kakhulu.
I-Gemfibrozil (Lopid)
Ukuthatha i-niacin kanye ne-gemfibrozil kungadala ukulimala kwemisipha kwabanye abantu. Sebenzisa ngokuqapha.
Imithi yesifo sikashukela (Imithi elwa nesifo sikashukela)
Ukusetshenziswa kwemithamo ephezulu ye-niacin (cishe u-3-4 amagremu nsuku zonke) kungakhuphula ushukela wegazi. Ngokwandisa ushukela wegazi, i-niacin inganciphisa ukusebenza kwemithi yesifo sikashukela. Bheka ushukela wegazi lakho eduze. Umthamo wemithi yakho yesifo sikashukela ungadinga ukuguqulwa.

Eminye imithi esetshenziselwa isifo sikashukela ifaka i-glimepiride (Amaryl), i-glyburide (i-DiaBeta, i-Glynase PresTab, i-Micronase), i-insulin, i-pioglitazone (i-Actos), i-rosiglitazone (i-Avandia), i-metformin (i-Glucophage), i-nateglinide (i-Starlix), i-repaglinide (i-Prandin), i-chlorpropamide (i-chlorpropamide) I-Diabinese), i-glipizide (iGlucotrol), i-tolbutamide (i-Orinase), nabanye.
Imithi yokwelapha umfutho wegazi ophakeme (Imithi efuthayo)
Ukusebenzisa i-niacin nezidakamizwa ezehlisa umfutho wegazi kungakhuphula imiphumela yale mithi futhi kungehlise umfutho wegazi kakhulu.

Eminye imishanguzo yomfutho wegazi ophakeme ihlanganisa i-captopril (Capoten), i-enalapril (i-Vasotec), i-losartan (i-Cozaar), i-valsartan (i-Diovan), i-diltiazem (i-Cardizem), i-amlodipine (i-Norvasc), i-hydrochlorothiazide (i-HydroDIURIL), i-furosemide (i-Lasix), neminye eminingi .
Imithi engalimaza isibindi (izidakamizwa ze-Hepatotoxic)
I-Niacin ingalimaza isibindi. Amalungiselelo e-niacin akhululwa aqinile abonakala enengozi enkulu kakhulu. Ukuthatha i-niacin kanye nemithi engalimaza nesibindi kungakhuphula ubungozi bokulimala kwesibindi. Ungathathi i-niacin uma uthatha umuthi ongalimaza isibindi.

Eminye imishanguzo engalimaza isibindi ifaka i-acetaminophen (Tylenol neminye), amiodarone (Cordarone), carbamazepine (Tegretol), isoniazid (INH), methotrexate (Rheumatrex), methyldopa (Aldomet), fluconazole (Diflucan), itraconazole (Sporaconazole) i-erythromycin (i-Erythrocin, i-Ilosone, abanye), i-phenytoin (i-Dilantin), i-lovastatin (i-Mevacor), i-pravastatin (i-Pravachol), i-simvastatin (i-Zocor), nezinye eziningi.
Imithi eyehlisa ukunqamuka kwegazi (Anticoagulant / Antiplatelet drug)
I-Niacin inganciphisa ukuvimba kwegazi. Ukuthatha i-niacin kanye nemithi nayo ejija kancane ukuvimba kungandisa amathuba okulinyazwa nokopha.

Eminye imithi eyehlisa ijubane ukuvala igazi ifaka phakathi i-aspirin, i-clopidogrel (i-Plavix), i-dalteparin (i-Fragmin), i-enoxaparin (i-Lovenox), i-heparin, i-indomethacin (i-Indocin), i-ticlopidine (i-Ticlid), i-warfarin (i-Coumadin), neminye.
Imithi esetshenziselwa ukwehlisa i-cholesterol (i-Bile acid sequestrants)
Eminye imishanguzo yokwehlisa i-cholesterol ebizwa nge-bile acid sequestrants inganciphisa ukuthi i-niacin engakanani emzimbeni oyiphuzayo. Lokhu kunganciphisa ukusebenza kwe-niacin. Thatha i-niacin kanye nemithi okungenani amahora angama-4-6 ahlukene.

Eminye yale mithi esetshenziselwa ukwehlisa i-cholesterol ifaka phakathi i-cholestyramine (i-Questran) ne-colestipol (i-Colestid).
Imithi esetshenziselwa ukwehlisa i-cholesterol (ama-Statins)
I-Niacin ingathinta kabi imisipha. Eminye imithi esetshenziselwa ukwehlisa i-cholesterol ebizwa ngama-statins nayo ingathinta imisipha. Ukuthatha i-niacin kanye nale mithi kungakhuphula ubungozi bezinkinga zemisipha.

Eminye yale mithi esetshenziselwa i-cholesterol ephezulu ifaka i-rosuvastatin (Crestor), i-atorvastatin (i-Lipitor), i-lovastatin (i-Mevacor), i-pravastatin (i-Pravachol), i-fluvastatin (i-Lescol), ne-simvastatin (i-Zocor).
I-Probenecid (Benemid)
I-Probenecid isetshenziselwa ukwelapha i-gout. Ukuthatha imithamo emikhulu ye-niacin kungalimaza i-gout futhi kwehlise ukusebenza kwe-probenecid.
I-Sulfinpyrazone (Anturane)
I-Sulfinpyrazone (Anturane) isetshenziselwa ukwelapha i-gout. Ukuthatha imithamo emikhulu ye-niacin kungalimaza i-gout futhi kwehlise ukusebenza kwe-sulfinpyrazone (Anturane).
Indlala yegilo
Umzimba ngokwemvelo ukhiqiza ama-hormone e-thyroid. I-Niacin inganciphisa amazinga e-hormone ye-thyroid. Ukuthatha i-niacin ngamaphilisi e-hormone yegilo kunganciphisa imiphumela kanye nemiphumela emibi yehomoni yegilo.
Okuncane
Qaphela ngale nhlanganisela.
I-Aspirin
I-Aspirin ivame ukusetshenziswa ne-niacin ukunciphisa ukuqhuma okubangelwa yi-niacin. Ukuthatha imithamo ephezulu ye-aspirin kunganciphisa ukuthi umzimba ususa kanjani i-niacin ngokushesha okukhulu. Lokhu kungadala ukuthi kube ne-niacin eningi kakhulu emzimbeni futhi kungaholela emiphumeleni emibi. Kodwa-ke, imithamo ephansi ye-aspirin esetshenziswa kakhulu ukugeleza okuhlobene ne-niacin akubonakali kuyinkinga.
Isichibi seNicotine (Nicoderm)
I-Niacin kwesinye isikhathi ingadala ukugeleza nesiyezi. Isiqephu se-nicotine naso singadala ukugeleza nesiyezi. Ukuthatha i-niacin noma i-niacinamide nokusebenzisa isichibi se-nicotine kungakhuphula amathuba okuba ugcwale futhi ube nesiyezi.
I-Beta-carotene
Inhlanganisela ye-niacin kanye nemithi kadokotela simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol enhle") kubantu abanesifo senhliziyo namazinga aphansi e-HDL. Kodwa-ke, ukuthatha i-niacin kanye nezinhlanganisela zama-antioxidants, kufaka phakathi i-beta-carotene, kubonakala ngathi kwenza lokhu kuphakama kwe-HDL kube lula. Akwaziwa noma lo mphumela uyenzeka kubantu abangenaso isifo senhliziyo.
I-Chromium
Ukuthatha i-niacin ne-chromium ndawonye kunganciphisa ushukela wegazi. Uma unesifo sikashukela futhi uthatha izithako ze-chromium ne-niacin ndawonye, ​​qapha ushukela wegazi lakho ukuze uqiniseke ukuthi awubi phansi kakhulu.
Amakhambi nezithako ezingalimaza isibindi
I-Niacin, ikakhulukazi ngemithamo ephakeme ingadala ukulimala kwesibindi. Ukuthatha i-niacin kanye namanye amakhambi noma izithasiselo ezingalimaza isibindi kungakhuphula le ngozi. Eminye yale mikhiqizo ifaka i-androstenedione, iqabunga le-borage, i-chaparral, i-comfrey, i-dehydroepiandrosterone (i-DHEA), i-germander, i-kava, i-pennyroyal oil, imvubelo ebomvu, neminye.
Amakhambi nezengezo ezinganciphisa umfutho wegazi
I-Niacin inganciphisa umfutho wegazi. Ukuthatha i-niacin namanye amakhambi nezithasiselo nazo ezinciphisa umfutho wegazi kungadala ukuthi umfutho wegazi wehle kakhulu. Amanye amakhambi nezithasiselo ezinganciphisa umfutho wegazi zifaka i-andrographis, i-casein peptides, uzipho lwekati, i-coenzyme Q10, i-L-arginine, i-lycium, i-nettle ehlabayo, i-theanine, nezinye.
Amakhambi nezengezo ezinganciphisa ukujiya kwegazi
I-Niacin inganciphisa ukuvimba kwegazi. Ukusebenzisa i-niacin kanye namanye amakhambi kanye nezithasiselo nazo ezihamba kancane ekunqandeni kwegazi kungakhuphula ingozi yokopha kwabanye abantu. Amanye amakhambi alolu hlobo afaka i-angelica, i-clove, i-danshen, i-garlic, i-ginger, i-Panax ginseng, namanye.
Itiye likaKombucha
Kukhona ukukhathazeka okuthile ngokuthi itiye le-kombucha linganciphisa ukumuncwa kwe-niacin. Noma kunjalo, lokhu kudinga ukufundwa kabanzi.
Selenium
Inhlanganisela ye-niacin kanye nemithi kadokotela simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol enhle") kubantu abanesifo senhliziyo namazinga aphansi e-HDL. Kodwa-ke, ukuthatha i-niacin kanye nezinhlanganisela zama-antioxidants, kufaka phakathi i-selenium, kubonakala sengathi kubangela lokhu kuphakama kwe-HDL. Akwaziwa noma lo mphumela uyenzeka kubantu abangenaso isifo senhliziyo.
I-Tryptophan
Amanye ama-tryptophan kusuka ekudleni angaguqulwa abe yi-niacin emzimbeni. Ukuthatha i-niacin ne-tryptophan ndawonye kungakhuphula amazinga nemiphumela emibi ye-niacin.
Uvithamini C
Inhlanganisela ye-niacin kanye nemithi kadokotela simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol enhle") kubantu abanesifo senhliziyo namazinga aphansi e-HDL. Kodwa-ke, ukuthatha i-niacin kanye nezinhlanganisela zama-antioxidants, kufaka phakathi i-vitamin C, kubonakala sengathi kubangela lokhu kukhuphuka kwe-HDL. Akwaziwa noma lo mphumela uyenzeka kubantu abangenaso isifo senhliziyo.
Uvithamini E
Inhlanganisela ye-niacin kanye nemithi kadokotela simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol enhle") kubantu abanesifo senhliziyo namazinga aphansi e-HDL. Kodwa-ke, ukuthatha i-niacin kanye nezinhlanganisela zama-antioxidants, kufaka phakathi i-vitamin E, kubonakala sengathi kubangela lokhu kuphakama kwe-HDL. Akwaziwa noma lo mphumela uyenzeka kubantu abangenaso isifo senhliziyo.
Izinki
Umzimba ungenza i-niacin. Abantu abangondlekile futhi abanenkinga ye-niacin, njengezidakwa ezingapheli, benza i-niacin eyengeziwe uma bethatha i-zinc. Kungaba nobungozi obandayo bemiphumela emibi ehlobene ne-niacin njengokushaywa nokushaywa uma i-niacin ne-zinc zithathwa ndawonye.
Iziphuzo ezishisayo
I-Niacin ingadala ukugeleza nokuheha. Le miphumela ingakhuphuka uma i-niacin ithathwa ngesiphuzo esishisayo.
Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:
  • Jikelele: Olunye uhlu lwemikhiqizo yokwengeza yokudla lubala i-niacin kulebula ngokulingana kwe-niacin (NE). 1 mg we-niacin uyefana no-1 mg NE. Lapho i-niacin ifakwa kuhlu kwelebula njenge-NE, ingafaka nezinye izinhlobo ze-niacin futhi, kufaka phakathi i-niacinamide, i-inositol nicotinate, ne-tryptophan. Izibonelelo zokudla ezinconywayo zansuku zonke (RDAs) ze-niacin kubantu abadala zingama-16 mg NE kwabesilisa, i-14 mg NE yabesifazane, i-18 mg NE yabesifazane abakhulelwe, ne-17 mg NE yabesifazane abancelisayo.
  • Nge-cholesterol ephezulu: Imiphumela ye-niacin incike kumthamo. Amanani we-niacin aphansi njengo-50 mg futhi asetshenziswe njengama-gramu ayi-12 usuku ngalunye asetshenzisiwe. Kodwa-ke, ukwanda okukhulu kwe-HDL nokuncipha kwe-triglycerides kwenzeka ngo-1200 kuye ku-1500 mg / ngosuku. Imiphumela emikhulu ye-Niacin ku-LDL yenzeka ngo-2000 kuye ku-3000 mg / ngosuku. I-Niacin ivame ukusetshenziswa neminye imithi yokwenza ngcono amazinga e-cholesterol.
  • Ukuvimbela nokwelapha ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagra: 300-1000 mg nsuku zonke ngemithamo ehlukanisiwe.
  • Okwelapha ukuqina kwemithambo yegazi: Amanani we-niacin abe phezulu njengama-gramu ayi-12 nsuku zonke. Kodwa-ke, umthamo ongaba u-1 kuye ku-4 amagremu we-niacin nsuku zonke, uwedwa noma kanye nama-statins noma i-bile acid sequestrants (umuthi owehlisa i-cholesterol), usetshenziselwe iminyaka engafika kwengu-6.2.
  • Ukwehlisa ukulahleka koketshezi okubangelwa ubuthi bekholeraKusetshenziswe amagremu ama-2 nsuku zonke.
  • Ngamazinga angavamile egazi ngenxa yokwelashwa kwe-HIV / AIDSKusetshenziswe ama-gramu ama-2 nsuku zonke.
  • Nge-metabolic syndrome: 2 amagremu we-niacin athathwe nsuku zonke amasonto ayi-16. Kwezinye izimo, i-niacin 2 gram nsuku zonke, iyodwa noma ngalesi silinganiso, ithathwa kanye no-4 amagremu we-omega-3 ethyl esters kadokotela (Lovaza, GlaxoSmithKline Pharmaceuticals).
NGU-IV:
  • Ukuvimbela nokwelapha ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagraKusetshenziswe i-60 mg ye-niacin.
NJENGOBA ISITHOMBE:
  • Ukuvimbela nokwelapha ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagraKusetshenziswe i-60 mg ye-niacin.
IZINGANE

NGOMLOMO:
  • Jikelele: Izibonelelo zokudla ezinconywayo zansuku zonke (ama-RDA) ze-niacin ezinganeni zingu-2 mg NE wezinsana ezinezinyanga ezineminyaka engu-0-6, i-4 mg NE yezinsana ezinezinyanga eziyi-7-12 ubudala, i-6 mg NE yezingane ezineminyaka engu-1-3, I-8 mg NE yezingane ezineminyaka engu-4-8 ubudala, i-12 mg NE yezingane ezineminyaka engu-9-13 ubudala, i-16 mg NE yabafana abaneminyaka engu-14-18 ubudala, ne-14 mg NE yamantombazane aneminyaka engu-14-18 ubudala.
  • Ukuvimbela nokwelapha ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagra: 100-300 mg ngosuku lwe-niacin, enikezwa ngemithamo ehlukanisiwe.
3-Pyridinecarboxylic Acid, Acide Nicotinique, Acide Pyridine-Carboxylique-3, Anti-Blacktongue Factor, Antipellagra Factor, B Complex Vitamin, Complexe de Vitamines B, Facteur Anti-Pellagre, Niacina, Niacine, Nicosedine, Nicotinra Aciding, I-Nicotinic Aciding, I-Nicotinra Acid Vitamin B3, Vitamin PP, Vitamina B3, Vitamine B3, Vitamine PP.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.


  1. UAnderson TJ, uGrégoire J, uPearson GJ, et al. Imihlahlandlela Yenhlangano Yezinhliziyo Yezinhliziyo ZaseCanada ka-2016 Yokuphathwa Kwe-Dyslipidemia Yokuvimbela Isifo Senhliziyo Kumuntu Omdala. Can J Cardiol. 2016; 32: 1263-1282. Buka okungaqondakali.
  2. UStone NJ, uRobinson JG, uLichtenstein AH, et al. Umhlahlandlela we-ACC / AHA ka-2013 ekwelapheni i-cholesterol egazini ukunciphisa ingozi ye-atherosclerotic yenhliziyo kubantu abadala: umbiko weqembu le-American College of Cardiology / American Heart Association ngeziqondiso zokusebenza. UJ Am Coll Cardiol 2014; 63: 2889-934. Buka okungaqondakali.
  3. ULloyd-Jones DM, uMorris PB, uBallantyne CM, et al. Isinqumo sokuvumelana kwesazi se-ACC se-ACC endimeni yezindlela ezingezona eze-statin zokwelashwa kwe-LDL-cholesterol ekwehliseni ukuphathwa kwe-atherosclerotic cardiovascularisifo sengozi: umbiko weqembu laseMelika College of Cardiology emibhalweni yochwepheshe bemitholampilo. UJ Am Coll weCardiol 2016; 68: 92-125. Buka okungaqondakali.
  4. UMontserrat-de la Paz S, uLopez S, uBermudez B, et al. Imiphumela ye-niacin ekhishwa ngokushesha kanye nama-acid okunamafutha ekudleni kwe-insulin enamandla kanye nesimo se-lipid kubantu abane-metabolic syndrome. J Sci Ukudla Agric 2018; 98: 2194-200. Buka okungaqondakali.
  5. UJenkins DJA, Spence JD, Giovannucci EL, et al. Amavithamini engeziwe kanye namaminerali okuvimbela nokwelashwa kwe-CVD. UJ Am Coll Cardiol 2018; 71: 2570-84. Buka okungaqondakali.
  6. USahebkar A, uReiner Z, uSimental-Mendia LE, uFerretti G, uCicero AF. Umphumela we-niacin ekhishwe isikhathi eside kumazinga e-plasma lipoprotein (a): Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kwezilingo ezilawulwa ngokungahleliwe ze-placebo. Umzimba. 2016 Nov; 65: 1664-78. Buka okungaqondakali.
  7. UGaynon MW, uPaulus YM, uRahimy E, u-Alexander JL, uMansour SE. Umphumela we-niacin yomlomo ekuvalekeni kwe-vein central retinal. Amathuna i-Arch Clin Exp Ophthalmol. 2017 Juni; 255: 1085-92. Buka okungaqondakali.
  8. USchandelmaier S, uBriel M, uSaccilotto R, u-Olu KK, u-Arpagaus A, uHemkens LG, uNordmann AJ. I-Niacin yokuvimbela okuyisisekelo nokwesibili kwemicimbi yenhliziyo. ICochrane Database Syst Rev. 2017 Jun 14; 6: CD009744. Buka okungaqondakali.
  9. ULin C, uGraninetti A, uShikuma C, et al. Imiphumela yokukhishwa kwe-niacin enwetshiwe kuma-lipoprotein sub-particle concentrations ezigulini ezinegciwane lesandulela ngculaza. IHawaii J Med Impilo Yomphakathi. 2013 Ephreli; 72: 123-7. Buka okungaqondakali.
  10. UScoffone HM, uKrajewski M, uZorca S, et al. Umphumela we-niacin ekhishwe isikhathi eside kuma-serum lipids nasemsebenzini we-endothelial kubantu abadala abane-sickle cell anemia kanye namazinga aphansi we-lipoprotein cholesterol. NginguJ Cardiol. 2013 Nov 1; 112: 1499-504. Buka okungaqondakali.
  11. UBrunner G, Yang EY, Kumar A, et al. Umphumela wokuguqulwa kwe-lipid kwisifo semithambo yomzimba ngemuva kwesilingo sokungenelela kwe-endovascular (ELIMIT). I-atherosclerosis. 2013 Dis; 213: 371-7. Buka okungaqondakali.
  12. UGoldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Ukwelashwa kwe-Niacin kanye nengozi yesifo sikashukela esisha: ukuhlaziywa kwe-meta kwezilingo ezilawulwa ngokungahleliwe. Inhliziyo. 2016 Feb; 102: 198-203. Buka okungaqondakali.
  13. Idokhumenti ye-PL, Indima Yezinto Ezingezona Izitatimende zeDyslipidemia. Incwadi KaPhemistri / Incwadi KaPrescriber. Juni 2016; 32: 320601.
  14. Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE; Abaphenyi be-AIM-HIGH. Ukwelashwa kwe-niacin enwetshiwe kanye nobungozi bokushaywa yischemic ezigulini ezinesifo senhliziyo: i-Atherothrombosis Intervention in Metabolic Syndrome ene-HDL / High Triglycerides: Impact ku-Global Health Outcome (AIM-HIGH). Unhlangothi. 2013 Okthoba; 44: 2688-93. Buka okungaqondakali.
  15. UShearer GC, uPottala JV, uHansen SN, uBrandenburg V, uHarris WS. Imiphumela ye-niacin kadokotela ne-omega-3 fatty acids kuma-lipids nomsebenzi we-vascular ku-metabolic syndrome: isilingo esilawulwa ngokungahleliwe. J Lipid Res. 2012 uNov; 53: 2429-35. Buka okungaqondakali.
  16. ISazonov V, iMaccubbin D, iSisk CM, iCanner PL. Imiphumela ye-niacin ekwenzekeni kwesifo sikashukela esisha kanye nemicimbi yenhliziyo ezigulini ezine-normoglycaemia kanye ne-glucose yokuzila engasebenzi kahle. I-Int J Clin Pract. 2013 Ephreli; 67: 297-302. Buka okungaqondakali.
  17. UPhilpott AC, uHubacek J, uSun YC, uHillard D, noAnderson TJ. I-Niacin ithuthukisa iphrofayli ye-lipid kepha hhayi ukusebenza kwe-endothelial ezigulini ezinesifo semithambo yenhliziyo ekwelashweni okuphezulu kwe-statin therapy. I-atherosclerosis. 2013 Feb; 226: 453-8. Buka okungaqondakali.
  18. ULoebl T, Raskin S. Umbiko wecala lenoveli: isiqephu esibuhlungu se-manic psychotic ngemuva kokwelashwa nge-niacin. Umtholampilo waseJ Neuropsychiatry Neurosci. Ukuwa kuka-2013; 25: E14. Buka okungaqondakali.
  19. UNdunankulu waseLavigne, uKaras RH. Isimo samanje se-niacin ekuvimbeleni izifo zenhliziyo: ukubuyekezwa okuhlelekile kanye ne-meta-regression. UJ Am Coll Cardiol. 2013 uJan 29; 61: 440-6. Buka okungaqondakali.
  20. ILakey WC, iGreyshock N, iGuyton JR. Ukusabela okungahambi kahle kwe-Achilles tendon xanthomas ezigulini ezintathu ze-hypercholesterolemic ngemuva kokuqiniswa kokwelashwa nge-niacin ne-bile acid sequestrants. J Clin Lipidol. 2013 Mar-Ephreli; 7: 178-81. Buka okungaqondakali.
  21. UKei A, Liberopoulos EN, Mikhailidis DP, Elisaf M. Ukuqhathaniswa kokushintshela kumthamo ophakeme kakhulu we-rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. I-Int J Clin Pract. 2013 Meyi; 67: 412-9. Buka okungaqondakali.
  22. UKeene D, Intengo C, uShun-Shin MJ, uFrancis DP. Imiphumela engcupheni yenhliziyo yemithambo yokwelashwa okuphezulu okubhekiswe ekwelapheni i-niacin, fibrate, kanye ne-CETP inhibitors: ukuhlaziywa kwe-meta kokuhlolwa okungahleliwe okulawulwa okubandakanya iziguli eziyi-117,411. BMJ. 2014 Julayi 18; 349: g4379. Buka okungaqondakali.
  23. Yena YM, Feng L, Huo DM, Yang ZH, Liao YH. Izinzuzo nokulimala kwe-niacin kanye ne-analog yayo yeziguli ze-renal dialysis: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. Int Urol Nephrol. 2014 Feb; 46: 433-42. Buka okungaqondakali.
  24. UGuyton JR, Fazio S, Adewale AJ, Jensen E, Tomassini JE, Shah A, Tershakovec AM. Umphumela we-niacin ekhishwe isikhathi eside kusifo sikashukela esisha phakathi kweziguli ze-hyperlipidemic eziphathwe nge-ezetimibe / simvastatin esivivinyweni esilawulwa ngokungahleliwe. Ukunakekelwa yisifo sikashukela. 2012 Ephreli; 35: 857-60. Buka okungaqondakali.
  25. UDavidson MH, uRooney M, uPollock E, uDrucker J, uChoy Y. Umphumela we-colesevelam ne-niacin ku-low-density lipoprotein cholesterol kanye nokulawulwa kwe-glycemic ezifundweni ezine-dyslipidemia kanye ne-glucose yokuzila engasebenzi kahle. J Clin Lipidol. 2013 Septhemba-Oct; 7: 423-32. Buka okungaqondakali.
  26. UBassan M. Icala le-niacin ekhishwa ngokushesha. Umkhuhlane Wenhliziyo. 2012 Jan-Feb; 41: 95-8. Buka okungaqondakali.
  27. I-Aramwit P, i-Srisawadwong R, i-Supasyndh O. Ukusebenza nokuphepha kwe-nicotinic acid ekhishwe isikhathi eside yokwehlisa i-serum phosphorus ezigulini ze-hemodialysis. UJ Nephrol. 2012 uMeyi-Juni; 25: 354-62. Buka okungaqondakali.
  28. U-Ali EH, McJunkin B, Jubelirer S, Hood W. Niacin wenze i-coagulopathy njengesibonakaliso sokulimala kwesibindi semilingo. W V Med J. 2013 Jan-Feb; 109: 12-4 Buka okungaqondakali.
  29. U-Urberg, M., Benyi, J., noJohn, R. Imiphumela ye-Hypocholesterolemic ye-nicotinic acid kanye ne-chromium supplementation. J Fam Khipha. 1988; 27: 603-606. Buka okungaqondakali.
  30. I-Hendrix, i-CR, i-Housh, i-TJ, i-Mielke, i-M, i-Zuniga, i-JM, i-Camic, i-CL, i-Johnson, i-GO, i-Schmidt, i-RJ, ne-Housh, imiphumela emibi ye-DJ yesengezo esiqukethe i-caffeine ekucindezelweni kwebhentshi namandla wokunweba emlenzeni nesikhathi ukukhathala phakathi nomjikelezo we-ergometry. J Amandla.Cond. Res 2010; 24: 859-865. Buka okungaqondakali.
  31. I-Figge HL, i-Figge J, i-Souney PF, et al. Ukuqhathanisa ukukhishwa kwe-nicotinuric acid ngemuva kokungeniswa kwamalungiselelo e-nicotinic acid amabili alawulwayo kumuntu. UJ Clin Pharmacol. Ngo-1988 uDec; 28: 1136-40. Buka okungaqondakali.
  32. UMrochek JE, uJolley RL, i-Young DS, iTurner WJ. Impendulo yeMetabolic yabantu ekufakeni i-nicotinic acid ne-nicotinamide. Umtholampilo Chem. 1976; 22: 1821-7. Buka okungaqondakali.
  33. I-Neuvonen PJ, Roivas L, Laine K, Sundholm O. Ukutholakala kokutholakala kokukhishwa okuqhubekayo kwe-nicotinic acid formulations. UBr J Clin Pharmacol. 1991; 32: 473-6. Buka okungaqondakali.
  34. UMenon RM, u-Adams MH, uGonzález MA, uTolbert DS, uLeu JH, uCefali EA. I-Plasma ne-urine pharmacokinetics ye-niacin kanye nama-metabolite ayo kusuka ekwakhiweni kwe-niacin enwetshiwe. I-Int J Clin Pharmacol Ther. 2007; 45: 448-54. Buka okungaqondakali.
  35. UKarpe F, uFrayn KN. I-nicotinic acid receptor - indlela entsha yomuthi wakudala. I-Lancet. 2004; 363: 1892-4. Buka okungaqondakali.
  36. Amacala S, Smith SJ, Zheng YW, et al. Ukukhonjwa kofuzo olufaka i-acyl CoA: i-diacylglycerol acyltransferase, i-enzyme eyinhloko ekuhlanganisweni kwe-triacylglycerol synthesis. I-Proc Natl Acad Sci U S A. 1998; 95: 13018-23. Buka okungaqondakali.
  37. UGanji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. I-Niacin ngokuncintisana ivimbela i-DGAT2 kepha hhayi umsebenzi we-DGAT1 kumaseli we-HepG2. J Lipid Res. 2004; 45: 1835-45. Buka okungaqondakali.
  38. UTornvall P, uHamsten A, uJohansson J, uCarlson LA. Ukujwayelekile kokwakheka kwe-lipoprotein ephansi kakhulu ku-hypertriglyceridemia yi-nicotinic acid. I-atherosclerosis. 1990; 84 (2-3): 219-27. Buka okungaqondakali.
  39. UMorgan JM, uCapuzzi DM, uBaksh RI, et al. Imiphumela ye-niacin ekhishwe isikhathi eside ekusatshalalisweni kwe-lipoprotein subclass. NginguJ Cardiol. 2003; 91: 1432-6. Buka okungaqondakali.
  40. UJin FY, uKamanna VS, uKashyap ML. I-Niacin inciphisa ukususwa kwe-high-density lipoprotein apolipoprotein A-I kepha hhayi i-cholesterol ester ngamaseli we-Hep G2. Impembelelo yokuthuthwa kwe-cholesterol eguqukayo. I-Arterioscler Thromb Vasc Biol. 1997; 17: 2020-8. Buka okungaqondakali.
  41. UVincent JE, uZijlstra FJ. I-Nicotinic acid ivimbela ukuhlanganiswa kwe-thromboxane kuma-platelets. Ama-Prostaglandins. 1978; 15: 629-36. Buka okungaqondakali.
  42. UDatta S, Das DK, Engelman RM, et al. Ukugcinwa okulondoloziwe kwe-myocardial yi-nicotinic acid, i-antilipolytic compound: indlela yokwenza. I-Basic Res Cardiol. 1989; 84: 63-76. Buka okungaqondakali.
  43. UTurjman N, uCardamone A, uGotterer GS, uHendrix TR. Umphumela we-nicotinic acid ekunyakazeni koketshezi okwenziwe yikholera kanye nokungaguquguquki kwe-sodium flux ku-rabbit jejunum. UJohn Hopkins Med J. 1980; 147: 209-11. Buka okungaqondakali.
  44. U-Unna K. Ucwaningo ngobuthi nangokhemisi we-nicotinic acid. UJ Pharmacol Exp Ther 1939; 65: 95-103.
  45. I-Brazda FG noCoulson RA. Ubuthi be-nicotinic acid nokunye okutholakele kukho. I-Proc Soc Exp Biol Med 1946; 62: 19-20.
  46. UChen KK, uRose CL, uRobbins EB. Ubuthi be-nicotinic acid. I-Proc Soc Exp Biol Med 1938; 38: 241-245.
  47. UFraunfelder FW, uFraunfelder FT, Illingworth DR. Imiphumela emibi ye-ocular ehlotshaniswa nokwelashwa kwe-niacin. UBr J Ophthalmol. 1995; 79: 54-56.
  48. I-Litin SC, no-Anderson CF. I-myopathy ehlobene neNicotinic acid: umbiko wamacala amathathu. NginguJ Med. 1989; 86: 481-3.
  49. UGharavi AG, uDiamond JA, uSmith DA, uPhillips RA. I-myopathy eyenziwe nge-Niacin. NginguJ Cardiol. 1994; 74: 841-2. Buka okungaqondakali.
  50. U-O’REILLY PO, CALLBECK MJ, HOFFER A. Ukukhishwa okuqinisiwe kwe-nicotinic acid (nicospan); umphumela emazingeni e-cholesterol nama-leukocyte. Ingabe uMed Assoc J. 1959; 80: 359-62. Buka okungaqondakali.
  51. Umhlaba TP, Odom L, Mullins CA. I-Lactic acidosis ehambisana nokwelashwa komthamo omkhulu we-niacin. INingizimu Med J. 1991; 84: 496-7. Buka okungaqondakali.
  52. I-Brown WV. I-Niacin yezinkinga ze-lipid. Izinkomba, ukusebenza, nokuphepha. I-Postgrad Med. 1995 Aug; 98: 185-9, 192-3. Buka okungaqondakali.
  53. UWindler E, uZyriax BC, uBamberger C, uRinninger F, uBeil FU. Amasu amanje nentuthuko yakamuva ekwelashweni kwe-hypercholesterolemia. I-Atheroscler Suppl. U-2009; 10: 1-4. Buka okungaqondakali.
  54. UKaijser L, u-Eklund B, u-Olsson AG, uCarlson LA. Ukuhlukaniswa kwemiphumela ye-nicotinic acid ku-vasodilatation ne-lipolysis yi-prostaglandin synthesis inhibitor, indomethacin, kumuntu. IMed Biol. 1979; 57: 114-7. Buka okungaqondakali.
  55. U-Eklund B, uKaijser L, uNowak J, uWennmalm A.I-Prostaglandins inegalelo ekuvuselweni kwe-vasodilation okubangelwa yi-nicotinic acid. Ama-Prostaglandins. 1979; 17: 821-30. Buka okungaqondakali.
  56. U-Andersson RG, Aberg G, Brattsand R, Ericsson E, Lundholm L. Ucwaningo ngomshini wokukhipha owenziwe yi-nicotinic acid. I-Acta Pharmacol Toxicol (iCopenh). 1977 Jul; 41: 1-10. Buka okungaqondakali.
  57. UMorgan JM, uCapuzzi DM, uGuyton JR, et al. Umphumela Wokwelapha we-Niaspan, i-Niacin ekhishwa elawulwayo, ezigulini ezine-Hypercholesterolemia: Isivivinyo esilawulwa yi-Placebo. UJ Cardiovasc Pharmacol Ther. 1996; 1: 195-202. Buka okungaqondakali.
  58. U-Aronov DM, uKeenan JM, u-Akhmedzhanov NM, et al. Ukuhlolwa komtholampilo kwe-wax-matrix okukhishwa okuqhubekayo kwe-niacin kubantu baseRussia abane-hypercholesterolemia. I-Arch Fam Med. 1996; 5: 567-75. Buka okungaqondakali.
  59. UGoldberg A, Alagona P Jr, uCapuzzi DM, et al. Ukusebenza kwamazinga amaningi nokuphepha kwefomu ekhishwe isikhathi eside ye-niacin ekuphathweni kwe-hyperlipidemia. NginguJ Cardiol. 2000; 85: 1100-5. Buka okungaqondakali.
  60. USmith DT, uRuffin JM, noSmith SG. I-Pellagra yelashwe ngempumelelo nge-nicotinic acid: umbiko wecala. IJAMA 1937; 109: 2054-2055.
  61. UFouts PJ, Helmer OM, Lepkovsky S, no-al. Ukwelashwa kwe-pellagra yomuntu nge-nicotinic acid. I-Proc Soc Exp Biol Med 1937; 37: 405-407.
  62. UBrown BG, uBardsley J, uPoulin D, et al. Umthamo olinganiselwe, ukwelashwa ngezidakamizwa ezintathu nge-niacin, lovastatin, ne-colestipol ukunciphisa i-low-density lipoprotein cholesterol <100 mg / dl ezigulini ezine-hyperlipidemia kanye ne-coronary artery disease. NginguJ Cardiol. 1997; 80: 111-5. Buka okungaqondakali.
  63. I-Ban TA. Izifundo zengqondo nezifundo zemikhakha yezemithi. IProg Neuropsychopharmacol Biol Psychiatry. Ngo-2006 Meyi; 30: 429-41.
  64. ULanska DJ. Isahluko 30: Izici zomlando zokuphazamiseka okukhulu kwamavithamini wezinzwa: amavithamini B ancibilikayo emanzini. I-Handb Clin Neurol. 2010; 95: 445-76. Buka okungaqondakali.
  65. IBerge KG, iCanner PL. Iphrojekthi yezidakamizwa zeCoronary: isipiliyoni nge-niacin. ICoronary Drug Project Group Iqembu. I-Eur J Clin Pharmacol. 1991; 40 Isengezo 1: S49-51. Buka okungaqondakali.
  66. Abekho ababhali abaklelisiwe. I-Clofibrate ne-niacin esifo senhliziyo. JAMA. Ngo-1975 uJan 27; 231: 360-81. Buka okungaqondakali.
  67. UHenkin Y, Oberman A, Hurst DC, Segrest JP. UNiacin uphinde wahlola: ukubonwa komtholampilo ngomuthi obalulekile kepha ongasetshenziswanga. NginguJ Med. 1991; 91: 239-46. Buka okungaqondakali.
  68. UHenkin Y, Johnson KC, Segrest JP. Rechallenge ne-crystalline niacin ngemuva kwe-hepatitis eyenziwe yizidakamizwa kusuka ku-niacin ekhishwe isikhathi eside. JAMA. 1990; 264: 241-3. Buka okungaqondakali.
  69. U-Etchason JA, uMiller TD, uSquires RW, et al. I-hepatitis eyenziwe nge-Niacin: umphumela ongaba khona we-side neacin ekhishwa isikhathi esincane. IMayo Clin Proc. 1991; 66: 23-8. Buka okungaqondakali.
  70. UShakir KM, uKoll S, u-Aprill BS, uDrake AJ 3rd, u-Eisold JF. I-Nicotinic acid inciphisa amazinga e-serum thyroid hormone ngenkathi igcina isimo se-euthyroid. IMayo Clin Proc. 1995; 70: 556-8. Buka okungaqondakali.
  71. UDrinka PJ. Ukuguqulwa kokuhlolwa kokusebenza kwe-thyroid kanye ne-hepatic okuhambisana nokulungiswa kwe-niacin ekhishwa okuqhubekayo. IMayo Clin Proc. 1992; 67: 1206. Buka okungaqondakali.
  72. UCashin-Hemphill L, uSpencer CA, uNicoloff JT, et al. Ukuguqulwa kwezimpawu ze-serum thyroid hormonal nge-colestipol-niacin therapy. U-Ann Intern Med. 1987; 107: 324-9. Buka okungaqondakali.
  73. UDunn RT, iFord MA, iRindone JP, i-Kwiecinski FA. I-Aspirin ephansi ne-Ibuprofen Yehlisa Ukusabela Okusikeka Ngokulandela Ukuphathwa Kwe-Niacin. NginguJ Ther. 1995; 2: 478-480. Buka okungaqondakali.
  74. I-Litin SC, no-Anderson CF. I-myopathy ehlobene neNicotinic acid: umbiko wamacala amathathu. NginguJ Med. 1989; 86: 481-3. Buka okungaqondakali.
  75. UHexeberg S, uRetterstøl K. [Hypertriglyceridemia - ukuxilonga, ubungozi nokwelashwa]. ITidsskr Noma iLaegeforen. 2004; 124: 2746-9. Buka okungaqondakali.
  76. UGarnett WR. Ukusebenzisana ne-hydroxymethylglutaryl-coenzyme A reductase inhibitors. NginguJ J Health Syst Pharm. 1995; 52: 1639-45. Buka okungaqondakali.
  77. IGadegbeku CA, Dhandayuthapani A, Shrayyef MZ, Egan BM. Imiphumela ye-Hemodynamic ye-nicotinic acid infusion ezifundweni ze-normotensive ne-hypertensive. NginguJ Hypertens. 2003; 16: 67-71. Buka okungaqondakali.
  78. U-O'Brien T, uSilverberg JD, uNguyen TT. Ubuthi obenziwe yiNicotinic acid obuhambisana ne-cytopenia namazinga anciphile e-globulin ebopha i-thyroxine. IMayo Clin Proc. 1992; 67: 465-8. Buka okungaqondakali.
  79. UDaring BD, uLavie CJ, uLohmann TP, uGenton E. Niacin obangelwa i-clotting factor synthesis defence ne-coagulopathy. I-Arch Intern Med. 1992; 152: 861-3. Buka okungaqondakali.
  80. USampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN. Ukukhishwa okunwetshiwe i-nicotinic acid - i-ejenti yomlomo yenoveli yokulawulwa kwe-phosphate. Int Urol Nephrol. 2006; 38: 171-4. Buka okungaqondakali.
  81. Ng CF, Lee CP, Ho AL, Lee VW. Umphumela we-niacin ekusebenzeni kwe-erectile emadodeni ahlushwa ukungasebenzi kahle kwe-erectile ne-dyslipidemia. J Ucansi Med. 2011; 8: 2883-93. Buka okungaqondakali.
  82. UDuggal JK, Singh M, Attri N, et al. Umphumela wokwelashwa kwe-niacin emiphumeleni yenhliziyo ezigulini ezinesifo semithambo yegazi. UJ Cardiovasc Pharmacol Ther. 2010; 15: 158-66. Buka okungaqondakali.
  83. UCarlson LA, uRosenhamer G. Ukunciphisa ukufa kwabantu eStockholm Ischemic Heart Disease Secondary Prevention Study ngokwelashwa okuhlangene ne-clofibrate ne-nicotinic acid. Acta Med Scand. 1988; 223: 405-18. Buka okungaqondakali.
  84. UBlankenhorn DH, uNessim SA, uJohnson RL, et al. Imiphumela ezuzisayo yokwelashwa okuhlangene kwe-colestipol-niacin ku-atherosclerosis ye-coronary kanye ne-coronary venous bypass grafts. JAMA. 1987; 257: 3233-40. Buka okungaqondakali.
  85. UMack WJ, uSelzer RH, uHodis HN, et al. Ukwehliswa konyaka owodwa nokuhlaziywa kwesikhathi eside kwe-carotid intima-media thickness ehambisana nokwelashwa kwe-colestipol / niacin. Unhlangothi. 1993; 24: 1779-83. Buka okungaqondakali.
  86. IBlankenhorn DH, uSelzer RH, uCrawford DW, et al. Imiphumela ezuzisayo yokwelashwa kwe-colestipol-niacin emthanjeni ojwayelekile we-carotid. Ukwehliswa kweminyaka emibili nemine yobukhulu be-intima-media kukalwa nge-ultrasound. Ukujikeleza. 1993; 88: 20-8. Buka okungaqondakali.
  87. UBrown BG, uZambon A, uPoulin D, et al. Ukusetshenziswa kwe-niacin, statins, kanye nama-resin ezigulini ezine-hyperlipidemia ehlangene. NginguJ Cardiol. 1998; 81 (4A): 52B-59B. Buka okungaqondakali.
  88. UBrown G, u-Albers JJ, uFisher LD, et al. Ukuhlehliswa kwesifo somthambo we-coronary ngenxa yokwelashwa okunciphisayo kwe-lipid emadodeni anezinga eliphakeme le-apolipoprotein B. N Engl J Med. 1990; 323: 1289-98. Buka okungaqondakali.
  89. UBruckert E, uLabreuche J, u-Amarenco P.Ukuhlaziywa kwemeta komphumela we-nicotinic acid yedwa noma ngokuhlanganiswa nemicimbi yenhliziyo nemithambo yegazi. I-atherosclerosis. 2010; 210: 353-61. Buka okungaqondakali.
  90. Izinhloli TD, Grant JM, Stone RE, et al. Ukuqaphela kwakamuva ekwelapheni ama-pellagrins angamakhulu ayisithupha ngokugcizelela okukhethekile ekusetshenzisweni kwe-nicotinic acid ku-prophylaxis. ISouth Med J 1938; 31: 1231.
  91. UMalfait P, uMoren A, uDillon JC, et al. Ukuqhamuka kwe-pellagra okuhlobene nezinguquko kwi-niacin yokudla phakathi kwababaleki baseMozambique eMalawi. I-Int J Epidemiol. 1993; 22: 504-11. Buka okungaqondakali.
  92. UGerber MT, uMondy KE, uYarasheski KE, et al. INiacin kubantu abanegciwane lesandulela ngculaza abane-hyperlipidemia ethola ukwelashwa okunamandla ngezidambisigciwane. I-Clin Infect Dis. 2004; 39: 419-25. Buka okungaqondakali.
  93. Ilungu lePhalamende laseDubé, uWu JW, u-Aberg JA, et al. Ukuphepha nokusebenza kwe-niacin ekhishwe isikhathi eside ekwelapheni i-dyslipidaemia ezigulini ezine-HIV: I-AIDS Clinical Trials Group Study A5148. Antivir Ther. 2006; 11: 1081-9. Buka okungaqondakali.
  94. UBalasubramanyam A, uCoraza I, uSmith EO, et al. Ukuhlanganiswa kwe-niacin ne-fenofibrate nokushintsha kwendlela yokuphila kuthuthukisa i-dyslipidemia ne-hypoadiponectinemia ezigulini ze-HIV ekwelashweni ngezidambisigciwane: imiphumela "yenhliziyo enhle," isilingo esilawulwa ngokungahleliwe. UJ Clin Endocrinol Metab. 2011; 96: 2236-47. Buka okungaqondakali.
  95. U-Elam MB, uHunninghake DB, uDavis KB, et al. Umphumela we-niacin kumazinga we-lipid ne-lipoprotein kanye nokulawulwa kwe-glycemic ezigulini ezinesifo sikashukela kanye nesifo semithambo yegazi: isifundo se-ADMIT: Isivivinyo esingahleliwe. Isifo Se-Arterial Izifo Eziningi Zokungenelela. JAMA. 2000; 284: 1263-70. Buka okungaqondakali.
  96. ICharland SL, iMalone DC. Ukubikezelwa kokuncishiswa komcimbi wenhliziyo nemithambo yegazi kusuka kuzinguquko ze-lipid ezihambisana nokwelashwa okuphezulu kwe-dyslipidemia. I-Curr Med Res Opin. 2010; 26: 365-75. Buka okungaqondakali.
  97. IGoldberg AC. Ukuhlaziywa kwemeta kwezifundo ezilawulwa ngokungahleliwe ngemiphumela ye-niacin ekhishwe isikhathi eside kwabesifazane. NginguJ Cardiol. 2004; 94: 121-4. Buka okungaqondakali.
  98. UMaes BD, uHiele MI, uGeypens BJ, et al. Ukushintshashintsha kwemithi kwesilinganiso sokukhipha isisu esiswini njengoba kulinganiswa yikhabhoni ebhalwe ukuthi i-octanoic acid test breath: ithonya le-erythromycin ne-propantheline. Amathumbu 1994; 35: 333-7. Buka okungaqondakali.
  99. Isitatimende se-FDA kusivivinyo se-AIM-HIGH. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm256841.htm. (Kufinyelelwe ngomhla ka-3 Juni 2011).
  100. Izindaba ze-NIH. I-NIH imisa isilingo somtholampilo ekwelashweni kwe-cholesterol ehlangene. Meyi 26, 2011.http://www.nih.gov/news/health/may2011/nhlbi-26.htm. (Kufinyelelwe ngomhla ka-3 Juni 2011).
  101. Umbhalo we-PL wemininingwane, i-Niacin Plus Statin Yokunciphisa Ingozi Yenhliziyo: Isifundo se-AIM-HIGH. Incwadi KaPhemistri / Incwadi KaPrescriber. Julayi 2011.
  102. UKarthikeyan K, Thappa DM. I-Pellagra nesikhumba. I-Int J Dermatol 2002; 41: 476-81. Buka okungaqondakali.
  103. Hendricks WM. I-Pellagra ne-pellagralike dermatoses: i-etiology, ukuxilongwa okwehlukile, i-dermatopathology, kanye nokwelashwa. USemin Dermatol 1991; 10: 282-92. Buka okungaqondakali.
  104. IBingham LG, iVerma SB. Ukuqhuma kwe-photodistribributed. (Ukuzihlola kwe-American Academy of Dermatology). J I-Acad Dermatol 2005; 52: 929-32.
  105. UNahata MC. I-chloramphenicol. Ku: Evans WE, Schentag JJ, Jusko WJ (eds). I-Pharmacokinetics Esetshenzisiwe: Izimiso Zokuqapha Izidakamizwa Ezelaphayo. 3rd ed., Vancouver, WA: I-Applied Therapeutics, Inc., 1992.
  106. UDing RW, uKolbe K, uMerz B, et al. I-Pharmacokinetics yokusebenzisana kwe-acid nicotinic acid-salicylic acid. I-Clin Pharmacol Ther 1989; 46: 642-7. Buka okungaqondakali.
  107. ILyon VB, iFairley JA. I-pellagra eyenziwe nge-Anticonvulsant. UJ I-Acad Dermatol 2002; 46: 597-9. Buka okungaqondakali.
  108. UKaur S, uGoraya JS, uThami GP, uKanwar AJ. I-Pellagrous dermatitis ebangelwa yi-phenytoin (incwadi). I-Pediatr Derm 2002; 19: 93. Buka okungaqondakali.
  109. UWood B, uRademaker M, u-Oakley A, uWallace J. Pellagra kowesifazane osebenzisa amanye amakhambi. I-Australas J Dermatol 1998; 39: 42-4. Buka okungaqondakali.
  110. I-Bender DA, i-pellagra eyenziwe ngu-Russell-Jones R. Isoniazid yize i-vitamin B6 ingezelela (incwadi). ILancet 1979; 2: 1125-6. Buka okungaqondakali.
  111. UStevens H, Ostlere L, Begent R, et al. I-Pellagra yesibili kuya ku-5-fluorouracil. UBr J Dermatol 1993; 128: 578-80. Buka okungaqondakali.
  112. USwash M, uRoberts AH. I-pellagra efana ne-encephalopathy efana ne-ethionamide ne-cycloserine. I-Tubercle 1972; 53: 132. Buka okungaqondakali.
  113. I-Brooks-Hill RW, uMbhishobhi ME, uVellend H. Pellagra-like encephalopathy efaka uxhaxha lwemithi eminingi yokwelapha ukutheleleka kwamaphaphu ngenxa ye-Mycobacterium avium-intracellulare (incwadi). NginguRev Rev Dis Dis 1985; 131: 476. Buka okungaqondakali.
  114. IBender DA, Earl CJ, Lees AJ. Ukuncipha kukaNiacin ezigulini zaseParkinsonia eziphathwe nge-L-dopa, benserazide ne-carbidopa. I-Clinical Sci 1979; 56: 89-93. . Buka okungaqondakali.
  115. ULudwig GD, i-White DC. I-Pellagra eyenziwe yi-6-mercaptopurine. I-Clin Res 1960; 8: 212.
  116. IStratigos JD, uKatsambas A. Pellagra: isifo esikhona namanje. UBr J Dermatol 1977; 96: 99-106. Buka okungaqondakali.
  117. UJarrett P, Duffill M, Oakley A, Smith A. Pellagra, azathioprine nezifo ezivuthayo zamathumbu. I-Clin Exp Dermatol 1997; 22: 44-5. Buka okungaqondakali.
  118. Imininingwane yomkhiqizo: Niaspan. I-Kos Pharmaceuticals. ECranbury, NJ. 2005. Itholakala ku-www.niaspan.com/professional/content/pdfs/productinfo.pdf. (Kufinyelelwe ngomhla ka-3 Mashi 2006).
  119. ISchwab RA, iBachhuber BH. I-Delirium ne-lactic acidosis ebangelwa yi-ethanol ne-niacin coingestion. Ngingu-J Emerg Med 1991; 9: 363-5. Buka okungaqondakali.
  120. Ito MK. Intuthuko ekuqondeni nasekuphathweni kwe-dyslipidemia: kusetshenziswa izindlela zokwelashwa ezisuselwa ku-niacin. NginguJ J Health-Syst Pharm 2003; 60 (suppl 2): ​​s15-21. Buka okungaqondakali.
  121. Imvubelo P, Witztum JL. I-Lovastatin, i-nicotinic acid ne-rhabdomyolysis (incwadi). U-Ann Int Med 1988; 109: 597-8. Buka okungaqondakali.
  122. Rockwell KA. Ukuxhumana okungaba khona phakathi kwe-niacin ne-transdermal nicotine (incwadi). U-Ann Pharmacother 1993; 27: 1283-4. Buka okungaqondakali.
  123. UGillman MA, Sandyk R.Nicotinic acid ukuntuleka okubangelwa yi-sodium valproate (incwadi). S Afr Med J 1984; 65: 986. Buka okungaqondakali.
  124. Ubaba CM. I-Niacinamide ne-acanthosis nigricans (incwadi). I-Arch Dermatol 1984; 120: 1281. Buka okungaqondakali.
  125. UMorris MC, u-Evans DA, uBianias JL, et al. I-Diac niacin kanye nengozi yesigameko i-Alzheimer's's kanye nokwehla kwengqondo. UJ Neurol Neurosurg Psychiatry 2004; 75: 1093-99. Buka okungaqondakali.
  126. UMcKenney J. Imibono emisha ngokusetshenziswa kwe-niacin ekwelapheni ukuphazamiseka kwe-lipid. I-Arch Intern Med 2004; 164: 697-705. Buka okungaqondakali.
  127. Ukukhulisa i-HDL nokusetshenziswa kwe-Niacin. Incwadi ka-Pharmacist's Letter / Prescriber's 2004; 20: 200504.
  128. IHoskin PJ, iStratford MR, iSaunders MI, et al. Ukuphathwa kwe-nicotinamide phakathi kweshadi: i-pharmacokinetics, ukukhuphuka komthamo, nobuthi bomtholampilo. I-Int J Radiat Oncol Biol Phys 1995; 32: 1111-9. Buka okungaqondakali.
  129. UMiralbell R, uMornex F, uGreiner R, et al. I-radiotherapy esheshayo, i-carbogen, ne-nicotinamide ku-glioblastoma multiforme: umbiko we-European Organisation for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999; 17: 3143-9. Buka okungaqondakali.
  130. Anon. I-Niacinamide Monograph. I-Alt Med Rev 2002; 7: 525-9. Buka okungaqondakali.
  131. ISchwartz ML. I-hyperglycemia ebuyela emuva enamandla ngenxa yokwelashwa kwe-niacin. I-Arch Int Med 1993; 153: 2050-2. Buka okungaqondakali.
  132. UKahn SE, uBeard JC, uSchwartz MW, et al. Ukwandisa amandla we-B-cell secretory njengendlela yokwenza i-islet adaptation to nicotinic acid-indased insulin insulin. Isifo sikashukela 1989; 38: 562-8. Buka okungaqondakali.
  133. URader JI, uCalvert RJ, uHathcock JN. Ubuthi be-hepatic bokulungiswa okungakhanyiswanga nesikhathi sokukhishwa kwe-niacin. NginguJ Med 1992; 92: 77-81. Buka okungaqondakali.
  134. I-Figge HL, i-Figge J, i-Souney PF, et al. I-Nicotinic acid: ukubuyekezwa kokusetshenziswa kwayo kwemitholampilo ekwelapheni ukuphazamiseka kwe-lipid. I-Pharmacotherapy 1988; 8: 287-94. Buka okungaqondakali.
  135. Amabhayi HE, iDujovne CA. Ukusebenzisana kwezidakamizwa ezidambisa lipid. Izidakamizwa Saf 1998; 19: 355-71. Buka okungaqondakali.
  136. UVannucchi H, uMoreno FS. Ukusebenzisana kwe-niacin ne-zinc metabolism ezigulini ezine-pellagra yotshwala. Ngingu-J J Nutriti 1989; 50: 364-9. Buka okungaqondakali.
  137. I-Urberg M, iZemel MB. Ubufakazi be-synergism phakathi kwe-chromium ne-nicotinic acid ekulawuleni ukubekezelelana kwe-glucose kubantu asebekhulile. I-Metabolism 1987; 36: 896-9. Buka okungaqondakali.
  138. UCheung MC, uZhao XQ, uChait A, et al. Izithako ze-antioxidant zivimba ukuphendula kwe-HDL ekwelashweni kwe-simvastatin-niacin ezigulini ezinesifo semithambo yenhliziyo ne-HDL ephansi. I-Arterioscler Thromb Vasc Biol 2001; 21: 1320-6. Buka okungaqondakali.
  139. UChesney CM, u-Elam MB, uHerd JA, et al. Umphumela we-niacin, warfarin, kanye ne-antioxidant therapy kumapharamitha we-coagulation ezigulini ezinesifo semithambo yegazi ku-Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000; 140: 631-6 .. Buka okungaqondakali.
  140. U-Wink J, uGiacoppe G, uKing J. Umphumela we-naicin ephansi kakhulu kwi-high-density lipoprotein ezigulini ezithola ukwelashwa kwe-statin isikhathi eside. Am Heart J 2002; 143: 514-8 .. Buka okungaqondakali.
  141. UWolfe ML, uVartanian SF, uRoss JL, et al. Ukuphepha nokusebenza kwe-Niaspan lapho ingezwa ngokulandelana kwi-statin ekwelapheni i-dyslipidemia. NginguJ J Cardiol 2001; 87: 476-9, A7 .. Buka okungaqondakali.
  142. UBrown BG, uZhao XQ, uChait A, et al. I-Simvastatin ne-niacin, amavithamini e-antioxidant, noma inhlanganisela yokuvimbela isifo se-coronary. N Engl J Med 2001; 345: 1583-93. Buka okungaqondakali.
  143. UCumming RG, Mitchell P, Smith W. Ukudla kanye ne-cataract: iBlue Mountains Eye Study. I-Ophthalmology 2000; 10: 450-6. Buka okungaqondakali.
  144. UKuroki F, u-Iida M, uTominaga M, et al. Isimo samavithamini amaningi kwisifo sikaCrohn. Ukuhlangana nomsebenzi wezifo. I-Dig Dis Sci 1993; 38: 1614-8. Buka okungaqondakali.
  145. IBhodi Yezokudla Nezokudla, Isikhungo Sezokwelapha. Ukufakwa Kwezikhombo Zezokudla ku-Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, neCholine. IWashington, DC: National Academy Press, 2000. Itholakala ku: http://books.nap.edu/books/0309065542/html/.
  146. Iwebhusayithi yeAmerican Dietetic Association. Kutholakala ku: www.eatright.org/adap1097.html (Kufinyelelwe ngomhlaka 16 Julayi 1999).
  147. ULal SM, uHewett JE, Petroski GF, et al. Imiphumela ye-nicotinic acid ne-lovastatin ezigulini zokufakelwa kwezinso: isilingo se-crossover esizoba khona, esingahleliwe, esinelebula evulekile. NginguJ J Kidney Dis 1995; 25: 616-22. Buka okungaqondakali.
  148. UGuyton JR, uGoldberg AC, uKreisberg RA, et al. Ukusebenza kokufakwa kwesisindo kanye kanye ebusuku kwe-niacin ekhishwe isikhathi eside iyodwa futhi ngokuhlangana kwe-hypercholesterolemia. NginguJ Cardiol 1998; 82: 737-43. Buka okungaqondakali.
  149. I-Vega GL, iGrundy SM. Izimpendulo ze-Lipoprotein ekwelashweni nge-lovastatin, gemfibrozil, ne-nicotinic acid kwiziguli ze-normolipidemic ezine-hypoalphalipoproteinemia. I-Arch Intern Med 1994; 154: 73-82. Buka okungaqondakali.
  150. I-Vacek JL, i-Dittmeier G, i-Chiarelli T, et al. Ukuqhathaniswa kwe-lovastatin (20 mg) ne-nicotinic acid (1.2 g) nomuthi owodwa wohlobo II hyperlipoproteinemia. NginguJ J Cardiol 1995; 76: 182-4. Buka okungaqondakali.
  151. U-Illingworth DR, uStein EA, uMitchel YB, et al. Imiphumela yokuqhathanisa ye-lovastatin ne-niacin ku-hypercholesterolemia eyinhloko. Ozoqulwa ecaleni. I-Arch Intern Med 1994; 154: 1586-95. Buka okungaqondakali.
  152. UPozzilli P, uBrowne PD, uKolb H. Meta-ukuhlaziywa kokwelapha i-nicotinamide ezigulini ezine-IDDM ezisanda kuqala. Izilingo zeNicotinamide. Ukunakekelwa yisifo sikashukela 1996; 19: 1357-63. Buka okungaqondakali.
  153. UJohansson JO, Egberg N, Asplund-Carlson A, Carlson LA. Ukwelashwa kweNicotinic acid kususa ibhalansi ye-fibrinolytic kahle futhi kunciphise i-plasma fibrinogen emadodeni e-hypertriglyceridaemic. J Cardiovasc Risk 1997; 4: 165-71. Buka okungaqondakali.
  154. URabbani GH, uButler T, uBardhan PK, u-Islam A.Ukuncipha kokulahleka koketshezi kukholera yi-nicotinic acid: isilingo esilawulwa ngokungahleliwe. ILancet 1983; 2: 1439-42. Buka okungaqondakali.
  155. Uhlelo Lukazwelonke Lwemfundo YeCholesterol. Ukwehla Kwecholesterol Esigulini Esinezifo Zenhliziyo Ezihlasela Coronary. 1997. Itholakala ku: http://www.vidyya.com/pdfs/1225cholesterol.pdf. (Kufinyelelwe ngomhla ka-26 Meyi 2016).
  156. UDarvay A, uBasarab T, uMcGregor JM, uRussell-Jones R. Isoniazid wenza i-pellagra naphezu kokungezelelwa kwe-pyridoxine. I-Clin Exp Dermatol 1999; 24: 167-9. Buka okungaqondakali.
  157. Ishii N, Nishihara Y. Pellagra encephalopathy phakathi kweziguli ezinesifo sofuba: ubudlelwane bayo nokwelashwa kwe-isoniazid. UJ Neurol Neurosurg Psychiatry 1985; 48: 628-34. Buka okungaqondakali.
  158. I-American Society of Health-System Pharmacists. Isitatimende Sesikhundla Sokwelashwa se-ASHP ngokusetshenziswa okuphephile kwe-niacin ekuphathweni kwe-dyslipidemias. NginguJ J Health Syst Pharm 1997; 54: 2815-9. Buka okungaqondakali.
  159. ILeighton RF, iGordon NF, i-GS Encane, et al. Ubuhlungu bamazinyo nobama-gingival njengemiphumela emibi yokwelashwa kwe-niacin. Isifuba 1998; 114: 1472-4. Buka okungaqondakali.
  160. UGarg A, uGundundy SM. I-Nicotinic acid njengokwelashwa kwe-dyslipidemia kwisifo sikashukela esingancikile ku-insulin. I-JAMA 1990; 264: 723-6. Buka okungaqondakali.
  161. I-Crouse JR III. Intuthuko entsha ekusetshenzisweni kwe-niacin ekwelapheni i-hyperlipidemia: ukucatshangelwa okusha ekusetshenzisweni kwesidakamizwa esidala. ICoron Artery Dis 1996; 7: 321-6. Buka okungaqondakali.
  162. I-Knopp RH. Amaphrofayli omtholampilo we-niacin ekhanyayo necacile ekhishwe eqhubekayo (i-Niaspan) kanye nomqondo we-physiologic we-dosing yasebusuku. NginguJ J Cardiol 1998; 82: 24U-28U; ingxoxo 39U-41U. Buka okungaqondakali.
  163. UKnopp RH, Alagona P, Davidson M, et al. Ukusebenza okulinganayo kwefomu ekhishwa ngesikhathi ye-niacin (Niaspan) enikezwe kanye-ubusuku kanye ne-niacin ecacile ekuphathweni kwe-hyperlipidemia. I-Metabolism 1998; 47: 1097-104. Buka okungaqondakali.
  164. UMcKenney JM, Proctor JD, Harris S, Chinchili VM. Ukuqhathaniswa kokusebenza kahle kanye nemiphumela enobuthi ye-niacin ekhishwa ngokushesha-ekhishwa ngokushesha ezigulini ze-hypercholesterolemic. I-JAMA 1994; 271: 672-7. Buka okungaqondakali.
  165. IGrey DR, uMorgan T, iChretien SD, iKashyap ML. Ukusebenza nokuphepha kwe-niacin ekhishwa ngokulawulwa kuma-veteran e-dyslipoproteinemic. U-Ann Intern Med 1994; 121: 252-8. Buka okungaqondakali.
  166. ICapuzzi DM, uGuyton JR, uMorgan JM, et al. Ukusebenza nokuphepha kwe-niacin ekhishwe isikhathi eside (i-Niaspan): isifundo sesikhathi eside. NginguJ J Cardiol 1998; 82: 74-81; i-disc. 85U-6U. Buka okungaqondakali.
  167. UJungnickel PW, Maloley PA, Vander Tuin EL, et al. Umphumela wezinhlobo ezimbili zemithi yokwelashwa ngaphambi kokuphathwa kwe-niacin. UJ Gen Intern Med 1997; 12: 591-6. Buka okungaqondakali.
  168. I-Whelan AM, Intengo SO, iFowler SF, iHainer BL. Umphumela we-aspirin ekuphenduleni kwe-niacin okubangelwa ukusikwa. UJ Fam Pract 1992; 34: 165-8. Buka okungaqondakali.
  169. IGibbons LW, uGonzalez V, uGordon N, uGrundy S. Ukusabalala kwemiphumela emibi nge-nicotinic acid ejwayelekile neqhubekayo. NginguJ Med 1995; 99: 378-85. Buka okungaqondakali.
  170. IPark YK, iSempos CT, iBarton CN, et al. Ukusebenza kokuqiniswa kokudla e-United States: icala le-pellagra. NginguJ J Health Public 2000; 90: 727-38. Buka okungaqondakali.
  171. UZhao XQ, uBrown BG, uHillger L, et al. Imiphumela yokwelashwa okunciphisayo kwe-lipid emithanjeni ye-coronary yezihloko ze-asymptomatic ezine-apolipoprotein ephakemeI-circulation 1993; 88: 2744-53. Buka okungaqondakali.
  172. ICanner PL, iBergge KG, uWenger NK, et al. Ukufa kweminyaka eyishumi nanhlanu ezigulini zeCoronary Drug Project: inzuzo yesikhathi eside nge-niacin. UJ Am Coll Cardiol 1986; 8: 1245-55. Buka okungaqondakali.
  173. UGuyton JR, ovutha MA, uHagar J, et al. I-niacin ekhishwe enwetshiwe vs gemfibrozil yokwelashwa kwamazinga aphansi we-high-density lipoprotein cholesterol. Iqembu le-Niaspan-Gemfibrozil Study. I-Arch Intern Med 2000; 160: 1177-84. Buka okungaqondakali.
  174. UZema MJ. I-Gemfibrozil, i-nicotinic acid kanye nokwelashwa kokuhlanganiswa kweziguli ezine-hypoalphalipoproteinemia ehlukanisiwe: isifundo esingahleliwe, esinelebuli evulekile, isifundo se-crossover. UJ Am Coll Cardiol 2000; 35: 640-6. Buka okungaqondakali.
  175. IKnodel LC, uTalbert RL. Imiphumela emibi yezidakamizwa ze-hypolipidaemic. IMed Toxicol 1987; 2: 10-32. Buka okungaqondakali.
  176. I-Yates AA, iSchlicker SA, iSuitor CW. Ukufakwa kwereferensi yokudla: Isisekelo esisha sezincomo ze-calcium nezakhi ezihlobene, amavithamini B, ne-choline. J Am Ukudla Assoc 1998; 98: 699-706. Buka okungaqondakali.
  177. I-Shils ME, u-Olson JA, uShike M, uRoss AC, ama-eds. Ukondleka Kwamanje Ezempilo Nezifo. Umhlaka 9. IBaltimore, MD: Williams & Wilkins, 1999.
  178. UReimund E. Ukulala okubangelwa ukulala okubangelwa ukulala: ukusekelwa okuqhubekayo kokuncipha kwe-nicotinic acid ekunciphiseni ubuthongo. I-Med Hypotheses 1991; 36: 371-3. Buka okungaqondakali.
  179. U-Ioannides-Demos LL, uChristophidis N, et al. Ukulinganisa imiphumela yokuhlangana komtholampilo phakathi kwejusi lamagilebhisi kanye ne-cyclosporine kanye nokugxila kwe-metabolite ezigulini ezinezifo ezizimele. UJ Rheumatol 1997; 24: 49-54. Buka okungaqondakali.
  180. UHardman JG, uLimbird LL, uMolinoff PB, ama-eds. UGoodman noGillman’s The Pharmacological Basis of Therapeutics, umhla ka-9. ENew York, NY: McGraw-Hill, 1996.
  181. UGarg R, uMalinow MR, uPettinger M, et al. Ukwelashwa kwe-Niacin kwandisa amazinga e-plasma homocysteine. Nginhliziyo J 1999; 138: 1082-7. Buka okungaqondakali.
  182. UGruenwald J, Brendler T, Jaenicke C. PDR weMithi Yemithi. 1st ed. IMontvale, NJ: I-Medical Economics Company, Inc., ngo-1998.
  183. UMcEvoy GK, umhleli. Imininingwane Yezidakamizwa ze-AHFS. I-Bethesda, MD: I-American Society of Health-System Pharmacists, ngo-1998.
Kugcine ukubuyekezwa - 10/16/2020

Okuthunyelwe Kwakamuva

I-Hangover yakho mhlawumbe ihlala isikhathi eside kunokuqonda kwakho
Ukudlala

I-Hangover yakho mhlawumbe ihlala isikhathi eside kunokuqonda kwakho

GiphyAmaHangover yiThe. Okubi kakhulu., Kepha kuvela ukuthi kungenzeka ukuthi bano hukela ngi ho nangaphezu kokuba ubona. Ucwaningo olu ha olu hicilelwe ephephabhukwini Umlutha ubheke imiphumela ukuph...
Ingabe Ukulawulwa Kwakho Kokubeletha Kubangela Izinkinga Zesisu?
Ukudlala

Ingabe Ukulawulwa Kwakho Kokubeletha Kubangela Izinkinga Zesisu?

Ukuqunjelwa, amajaqamba, i icanucanu yimiphumela emibi ejwayelekile yokuya e ikhathini. Kepha ngoku ho kocwaningo olu ha, izinkinga ze i u nazo zingaba umphumela ohlangothini wento e iyi a kuyo U izo ...